Early Cell Sorting for Biologics Production

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for selecting producer cell populations and clones for biologic manufacturing, such as those using methotrexate (MTX), are time-consuming, affect cell viability, and can impact clonal stability.

Innovation Solution

The method involves transfecting host cells with vectors encoding a selectable polypeptide and a target polypeptide, followed by the early sorting of transfected cells using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) within 2 to 15 days post-transfection, allowing for the expansion of a sub-population of producer cells in drug-selection-free medium.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional MTX-based selection methods are used to generate producer cell populations, then cell clones suitable for biologic manufacturing can be obtained, but the process is time-consuming and requires multiple rounds of selection

Engineering Contradiction:
Improveclonal stabilityVSAvoidselection time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by sorting cells for early expression of the target polypeptide immediately after transfection (within 2-15 days), before traditional multi-round MTX selection processes. This early sorting captures high-producing clones upfront, eliminating the need for multiple subsequent selection rounds and significantly reducing the overall selection timeline while maintaining clonal stability

Inventive Principle:
Principle #10Preliminary action

2Productivity

If drug-based selection agents like MTX or MSX are used to amplify biologic production, then producer cell populations can be selected, but cell viability and growth rate are affected negatively

Engineering Contradiction:
Improvebiologic production titerVSAvoidcell viability impact
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and eliminates the harmful drug-based selection agents (MTX, MSX) from the cell selection process. Instead, it uses direct sorting methods (FACS, MACS) to isolate cells based on their natural expression of the target polypeptide or selectable marker, achieving high-productivity producer populations without exposing cells to drugs that compromise viability and growth rate

Inventive Principle:
Principle #2Taking out (Extraction)

3Productivity

If multiple rounds of MTX selection are performed to generate suitable cell populations, then high-titer clones can be obtained, but the process complexity and time requirements increase

Engineering Contradiction:
Improvebiologic production titerVSAvoidselection process complexity
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The patent performs the critical selection action preliminarily by sorting for early expression immediately after transfection. This single early sorting event captures high-producing clones before they are lost during prolonged multi-round selection processes, simplifying the overall workflow from a complex multi-step MTX selection regimen to a more straightforward transfection-early sort-expansion protocol

Inventive Principle:
Principle #10Preliminary action

4Reliability

If traditional selection methods are used, then cell populations expressing target polypeptide can be generated, but the impact on host cell stability is negative

Engineering Contradiction:
Improveclonal stabilityVSAvoidcell population maintenance
Core Design Contradiction:
ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent removes harmful drug-based selection pressures that compromise long-term cell population stability. By using physical sorting methods (FACS, MACS) based on early expression markers, it selects for stable, high-producing clones without subjecting cells to chronic drug exposure that can cause genetic drift, reduced viability, and loss of clonal stability over time

Inventive Principle:
Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach is faster and more productive than traditional MTX-based methods, enabling the generation of high-titer clones suitable for both small and large-scale biologic manufacturing with reduced impact on host cell viability and stability.

Implementation Method 1

isolating employs fluorescence activated cell sorting (FACS) or magnetic activated cell sorting (MACS) on the selectable polypeptide

Methodology Applied
Scientific EffectFluorescence: Fluorescence

Implementation Method 2

isolating employs fluorescence activated cell sorting (FACS) or magnetic activated cell sorting (MACS) on the selectable polypeptide

Methodology Applied
Scientific EffectMagnetism: Magnetism

Data Source

PatentEP3523440B1Early post-transfection isolation of cells (EPIC) for biologics production
Publication Date: 2025.01.29 GENZYME CORP
  • EP3523440B1 patent drawingFigure 1A
  • EP3523440B1 patent drawingFigure 1B
  • EP3523440B1 patent drawingFigure 2

AI summary

Provided herein are methods for selecting a population of cells expressing a target polypeptide. In some aspects, the disclosure provides methods for sorting and selecting populations of transfected host cells based on their early expression of a selectable polypeptide. In certain embodiments, the sorting is performed using fluorescence-activated cell sorting or magnetic-activated cell sorting based on the selectable polypeptide. Such selection methods can be further utilized to generate clonal populations of producer cells, e.g. for large-scale manufacturing of a target polypeptide of interest.